Rights and permissions
About this article
Cite this article
Abciximab ‘highly cost effective’ in coronary disorders. Pharmacoecon. Outcomes News 226, 5 (1999). https://doi.org/10.1007/BF03275047
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03275047